Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
Information source: Los Angeles Biomedical Research Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Arterial Hypertension
Intervention: BPS-314d-MR (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: Los Angeles Biomedical Research Institute Official(s) and/or principal investigator(s):
Ronald J Oudiz, MD, Principal Investigator, Affiliation: Los Angeles BRI
Summary
The purpose of this study is to see if Lung LLC's new experimental formulation of the
medicine Beraprost Sodium, called Beraprost Sodium 314d Modified Release (BPS-314d-MR), can
improve the symptoms of pulmonary arterial hypertension (PAH) in patients. An experimental
drug is one that has not been approved by the U. S. Food and Drug Administration for use in
the general public. This research study is for patients who have pulmonary arterial
hypertension (PAH) and have just completed taking part in an earlier research study and
received an older experimental formulation of Beraprost Sodium, called Beraprost Sodium
Modified Release (BPS-MR). That earlier study was being done to see if BPS-MR could improve
their PAH.
Patients may also be taking Tyvaso (treprostinil), Tracleer (bosentan), Letairis
(ambrisentan), Adcirca (tadalafil) and/or Viagra or Revatio (sildenafil) to treat their PAH.
The diagnosis of PAH means that the blood pressure in their lungs is higher than normal. The
increased blood pressure in the lungs places a strain on the heart. The strain causes the
heart to pump less blood into the lungs, causing shortness of breath and tiredness. The
strain on the heart weakens the heart muscle making it less able to pump blood, a condition
called heart failure. As heart failure develops, swelling in the feet and abdomen may
occur.
Clinical Details
Official title: Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH).
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of participants experiencing Adverse Events
Detailed description:
According to Lung LLC, and from my review of summary results contained within the most
recent version of the BPS-314d-MR Investigators' Brochure I concur, BPS-314d- MR has been
shown to have a similar safety and pharmacokinetic profile in healthy volunteers to BPS-MR.
It is also my understanding that at an End of Phase II meeting in April of this year, FDA
acknowledged Lung LLC's intention to continue the development of BPS-314d-MR by conducting a
Phase III pivotal study in PAH patients. This study, BPS-314d-MR-PAH-302 was subsequently
initiated this past June.
In my opinion, and based upon the similarities of the two formulations, it is in the best
interest of our patients to transition their treatment to BPS-314d-MR.
Lung LLC has agreed to supply BPS-314d-MR for the patients.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Prior participation in Beraprost-MR study at Harbor-UCLA
Exclusion Criteria:
- No prior participation in Beraprost study at Harbor-UCLA
Locations and Contacts
Los Angeles Biomedical research Institute, Torrance, California 90502, United States
Additional Information
Starting date: November 2013
Last updated: May 27, 2015
|
